Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

JUNE 16, 2021

As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Veriheal

JULY 12, 2021

Fortunately, congressional committees are fighting for medical cannabis access for veterans , and states are beginning to take measures to address their veterans , but what is the latest in research and what can one expect? At this time, there is little in the way for combat-related PTSD treatment specifically. Let’s find out. .

Treatment 104

Treatment Sleep Clinical Trials Data 104

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

Cannabis Law Report

SEPTEMBER 15, 2021

Delta-8 tetrahydrocannabinol, also known as delta-8 THC, is a psychoactive substance found in the Cannabis sativa plant, of which marijuana and hemp are two varieties. Delta-8 THC is one of over 100 cannabinoids produced naturally by the cannabis plant but is not found in significant amounts in the cannabis plant.

THC 105

THC Pets Events Hemp 105

The Joint Blog

APRIL 17, 2020

Cannabis Sativa, a.k.a Its psychoactive ingredient, THC, has made cannabis a highly used recreational drug for millennia. Over the past few decades, there has been an increased interest in leveraging cannabis and cannabinoids for medicinal purpose. marijuana” is the one of the most popular illicit substances in the world.

Events 48

Events THC Chronic Pain Sleep 48

The Cannigma

OCTOBER 21, 2021

ADHD has long been tied to increased cannabis use, as well as abuse of drugs like alcohol and nicotine. Still, many patients report that cannabis helps them to feel more in control of their symptoms, leading to important questions. Can cannabis help with ADHD? Can cannabis help with ADHD? What is ADHD? 6 7 8 9.

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. “Our

Therapy 76

Therapy Data Research and Development Events 76

Veriheal

SEPTEMBER 15, 2021

Cannabis is increasingly being researched in various capacities. In order for you to better understand the many types of cannabis research, this guide has been put together for your convenience. In order for you to better understand the many types of cannabis research, this guide has been put together for your convenience.

Data 81

Data Collective Environment Cannabis 81

Illinois News Joint

APRIL 2, 2023

One of the comments we get most, especially after publishing monthly cannabis sales totals, is, “Where’s all that tax money going?” According to the CROO website, the Illinois Department of Revenue posts monthly updates how the Cannabis Regulation Fund gets distributed. For more Illinois cannabis industry news, visit here.

Education 84

Education Cannabis Collective Programs 84

SpeedWeed

MARCH 13, 2021

Almost 25% of patients with Parkinson’s disease reported that they had used cannabis in the prior six months in a survey from the Parkinson’s Foundation. However, common treatments do not address the non-motor symptoms and can sometimes cause side effects including dyskinesia, an abnormality or impairment of voluntary movement. .

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

The Joint Blog

MARCH 3, 2021

According to a new study published in the Journal of Cannabis Research, adjunctive marijuana use is associated with improvements in pain and other symptoms in patients with refractory fibromyalgia. The study is titled Medical cannabis for the treatment of fibromyalgia syndrome: A retrospective, open-label case series.

Therapy 61

Therapy Hybrid Marijuana Research and Development 61

Cannabis Law Report

JANUARY 23, 2022

I was a young cannabis research student on my first trip overseas to an international research conference. Events like these afford us a glimpse into the future of research and medicine in this field. At current, transplant treatments are hindered by our understanding of the immune response of those receiving treatments.

Research and Development 52

Research and Development Wellness and Beauty Patients CBD 52

The Joint Blog

JANUARY 3, 2020

Marijuana-based medicines “might be effective and safe in the treatment of tics and comorbidities” in those with Gilles de la Tourette Syndrome, according to a new study published in the journal Cannabis and Cannabinoids Research and e-published by the National Institute of Health.

Data 49

Data Treatment Marijuana Patients 49

Cannabis Law Report

AUGUST 10, 2021

The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% It is an honour and privilege to be in the position to use novel psychedelic treatments to solve the complex puzzle that is chronic pain. These statements relate to future events or future performance. billion in 2030. 3 Psychol Res Behav Manag.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

JULY 22, 2021

We believe that this will serve as a strong platform from which to deploy impactful alternative and psychedelic based treatment options,” stated Pouya Farmand, Chief Executive Officer of Levitee. About Levitee Labs. Levitee Labs is establishing itself as a leader in the integrative wellness space.

eCommerce 105

eCommerce Therapy Media Access 105

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021. Net loss for the six months ended 30 June 2021 was $30.2 million, or $0.79 million) compared with $24.8 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JULY 28, 2021

Active research includes applications of machine learning and data mining as a member of the University of Alberta computational psychiatry group. His knowledge and insight will be paramount as we continue to navigate the development of DMT as a treatment for addiction disorders,” said Chief Executive Officer, Timothy Ko.

Research and Development 105

Research and Development Events Media Data 105

Cannabis Law Report

SEPTEMBER 23, 2021

The major concerns noted were adverse events following consumption (many from inadvertent intoxication), marketing to and use by minors, and the potential presence of harmful by-products and unsafe manufacturing practices. The FDA has received adverse event reports involving delta-8 THC-containing products. CDC Health Alert.

THC 52

THC Concentrates Pets DEA 52

Freedom Leaf

JANUARY 4, 2018

“Our goal is to bring awareness of emerging innovation and opportunities to the East Coast regarding cannabis technology.” Cofounder, Jade Insights and Cannabis Tech Group, New York, N.Y. It’s a software platform that helps cannabis businesses augment their process by providing insights for data-backed decision-making.

Data 60

Data Policy Media Cannabis 60

The Joint Blog

JANUARY 21, 2020

Marijuana use is associated with subjective benefits in patients with Tourette Syndrome (TS), according to a new study published in the journal Cannabis and Cannabinoid Research. The study is titled Treatment of Gilles de la Tourette Syndrome in cannabis-based medicine: Results from a retrospective analysis and online survey.

Patients 29

Patients Marijuana Data Treatment 29

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

The Cannigma

OCTOBER 9, 2021

Studies demonstrate that cannabis and its cannabinoid constituents have an implication on human urinary function. The effects of cannabis on micturition are complex with many factors at play. Cannabis use in some individuals can cause excessive bouts of giggling and with giggle incontinence, can lead to the leaking of urine.

Cannabinoids 86

Cannabinoids Consumption Patients Cannabis 86

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

NOVEMBER 9, 2021

(“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S.

Treatment 52

Treatment Therapy Media Access 52

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

FEBRUARY 2, 2022

This application comes on the heels of Colombia’s new legislation requiring insurance companies to cover cannabis prescriptions. “I Dr. Manalo-Morgan has spent the last 5 years researching cannabis and has specialized in the formulation of cannabinoid products for clinical trials. About Flora Growth Corp.

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Cannabis Law Report

JANUARY 13, 2020

Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Puff Puff Post

MARCH 10, 2020

.” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JANUARY 12, 2022

As Oregon prepares to roll out the nation’s first legal psilocybin-assisted services program, there is a recognized need for the community to track adverse events and measure efficacy. Through the right mix of regulation, technology, and data, both are equally achievable,” says NPA CEO Britt Rollins.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

CannaMD

SEPTEMBER 15, 2020

SHORT ANSWER: In November 2016, the Florida Medical Marijuana Legalization Initiative (known as Amendment 2 ) legalized medical marijuana treatment in Florida. Patients suffering from cancer, epilepsy, chronic seizures, or muscle spasms could use low-THC cannabis products recommended by a licensed doctor. Qualified patient.

Law 126

Law Marijuana Patients Treatment 126